Summary Serum levels of mucin-like carcinoma associated antigen (MCA) were 
The search for tumour markers for the diagnosis, assessment and follow-up of breast cancer has until recently been disappointing. The long disease free interval that may occur between the treatment of the primary tumour and its eventual recurrence add particular difficulties when a marker is to be used to assess prognosis and for the early identification of recurrence. The criteria required for a clinically useful marker have been reviewed by Waalkes et al. (1984) and the limitations of analytes available at this time summarised by Coombes et al. (1982) . Carcinoembryonic antigen (CEA), the most widely used cancer marker, has been shown to be of value for monitoring the response to treatment in about 60% of advanced metastatic breast cancer but lacks the sensitivity and specificity to detect small tumour burdens (Lamerz et al., 1979) .
During the past 5 years the spectrum of breast cancer markers has increased considerably as monoclonal antibody (MAb) techniques have been applied to the problem. Several MAb antibodies have been raised with highly selective immunoreactivity against breast cancer cells which are generally high molecular weight glycoproteins. MAb immunoassays have been devised for the measurement of several of these glycoproteins. The novel tests include CA 15-3 (Hayes et al., 1986) , mucin-like carcinoma associated antigen (MCA) recognised by the antibody b-12 (Stahli et al., 1985 (Stahli et al., , 1989 Bieglmayer et al., 1988) , mammary serum antigen (Sacks et al., 1987) and CA 549 (Gaur et al., 1987; Chan et al., 1988) . Recently a commercial two-step enzyme-linked immunoassay (EIA) Follow-up Tumour-free In 20 patients presenting with stage I or II disease who have remained tumour-free for 5-9 years consecutive yearly serum samples were analysed for their MCA concentration. This set of patients was used to illustrate the intra-and inter-patient variation of MCA level during surveillance. The distribution of MCA levels was also examined in the most recent follow-up sample from a further 63 patients who presented with stage I or II disease and had remained tumour-free for 3-9 years. All serum samples were stored at -20°C until use.
Recurrence Serum samples were available from three patients with local recurrence and 14 with metastatic disease from whom there were antecedent serum samples available when they were tumour-free. Further sera were obtained from 45 patients with active metastatic disease who were not part of the longterm follow up study. All serum samples were stored at -20°C until use. Samples had been accumulated since 1979.
MCA assay The MCA-EIA (Roche Diagnostics, Welwyn Garden City, Herts) was used according to the manufacturer's instructions. The kit is a two-step solid phase enzyme immunoassay. The assay employs the same monoclonal mouse antibody to MCA (MAb b-12) in both positions of the sandwich (as capture antibody and as detection antibody), as this antibody recognises a repetitive binding site on the MCA molecule. In a first step, the patient's sera and MCA standards are incubated with MAb coated beads. After a washing step, anti-MCA peroxidase conjugate (anti-MCA antibody b-12 conjugated with horseradish peroxidase) is added. After a second incubation E.H. COOPER et al.
step, unbound anti-MCA peroxidase conjugate is removed by washing. Subsequently, the bead is incubated with enzyme substrate and the extent of the resulting colour is proportional to the amount of conjugate bound and hence to the amount of MCA in the specimen. The patient and control values are then determined by means of the standard curve as described in the manufacturer's instructions; the units of MCA were as defined by Stahli et al. (1989) .
A control sample, with a designated mean vtlue 13Uml-1, provided by the manufacturer, was measured at the beginning and end of each assay. The inter-and intraassay variation was also measured using a serum sample with a value nearer the top of the measuring range.
Results
The control sample measured in quadruplicate gave a mean value of 14.2Uml-1 measured on 10 runs with a coefficient of variation (CV) of 5.2%. The higher serum control with a mean value of 33.1 U ml1 had an inter-assay CV over five runs of 9.6%, and an intra-assay CV of 8.5% (20 replicates).
The mean (± s. Long-term follow-up The levels of MCA measured annually in 20 patients who have remained tumour-free are shown in Figure 2 . This shows the considerable between patient variation while the intra-patient levels remain within relatively narrow limits. The median level (and range) observed in the last available serum from a further 63 patients who were tumour-free for 3-9 years was 7.4Uml-1 (1-21.1) confirming the wide variance of the serum level of MCA in women who remain at risk of recurrent or metastatic disease being nearly the same as in healthy controls.
By contrast 12/14 patients who developed metastases 2-8 years after surgery and for whom serum samples were available in the bank, had rising MCA levels. Ten of these patients are illustrated in Figure 3 . In three patients who developed local recurrences there was no significant change of MCA level between when they were tumour free and had evidence of local recurrence.
Sera from a further 45 patients with active metastatic breast cancer attending for treatment were examined to determine the frequency of an elevated MCA level. Eighty per cent of these patients had an MCA value of > 15 U ml-1 and in 31 % the value was > 100 U ml-1. Longitudinal studies were made for 4-8 months in 12 patients who were receiving treatment for metastatic disease. Figure 4 illustrates the fall in the MCA level following treatment in five patients, another patient who was resistant to chemotherapy had a level of 20-30 U ml-1 sustained for 4 months. Changes of MCA level within the normal range can occur on treatment, in a patient with a level of 13 U ml-1 when presenting with metastases, the response to chemotherapy was associated with a sustained fall of MCA to <1 U ml-1.
One patient who was initially considered to have bone metastases but whose MCA level remained stable at less than 10 U ml-1 for several years had her diagnosis revised to Padget's disease.
Discussion
Mucin-like carcinoma associated antigen has been identified on the surface of mammary carcinoma cells by MAb b-12; immunoblot studies showed it had a relative molecular weight of 350,000 d (Stahli et al., 1985) . This epitope is also found in some normal mucinous epithelia including the distal kidney tubules and ductules of the breast (Stahli et al., 1985) . MCA contains primarily 0-linked carbohydrate side chains with sialic acid and hexoses including fucose (Stahli et al., 1989) . MCA belongs to the group of mucin-like glycoproteins (Stahli et al., 1989) released from breast cancers which include the Ca antigen (Bramwell, 1983) , CA 15-3 (Hayes et al., 1986) and human milk fat globule membranes (Hilkens et al., 1984; Turnbull et al., 1986) .
While the inter-relationships of these glycoproteins are still being elucidated (Stahli et al., 1989) , MCA is sufficiently interesting to warrant introduction as a commercially available test for breast cancer and our study has provided more clinical information about its performance.
The serum MCA levels in breast cancer at presentation show considerable overlap with healthy controls; there is a tendency for the levels to be higher in stage III with lymph node involvement and in stage IV. A similar phenomenon has been observed for CA 15-3 levels (Gion et al., 1986; Pons-Anciet et al., 1987; Hayes et al., 1986) . However, it is evident that MCA lacks the sensitivity needed for it to be used for population screening.
The variability of the latent period between primary breast cancer and the detection of recurrence or metastases is a well known characteristic of the disease. The use of stored samples has demonstrated the behaviour of MCA in patients who have remained tumour-free and in those who have developed recurrence or distant metastases. The essential feature is that each patient has his or her own level which tends to be stable, as evidenced by repeated samples, over a period of 5-9 years. The range is wide: < 1.0-21.0 U ml-1. In patients with MCA levels >11 U ml-1 as quoted by Roche for the upper limit of normal, caution is needed in the interpretation of a single observation, as some patients can have apparent elevation of MCA for many years without evidence of recurrence. However, during follow-up levels >25 U ml-1 were only seen in patients with metastatic cancer.
As with several other tumour markers, such as CA 50 and CA 15-3, there is considerable amplification of the level of MCA in disseminated metastatic disease, with increases of one to two orders of magnitude greater than the tumour-free level (Hayes et al., 1986; Bieglmayer et al., 1988 (1988) . Previous studies have shown that CA 15-3 is superior to CEA in follow-up and for the monitoring of metastatic breast cancer (Hayes et al., 1986; Pons-Anciet et al., 1987) .
The present study suggests that MCA can provide a useful marker for the follow-up of breast cancer patients. The frequency of measurement will influence the lead time, in our series the low risk patients were seen once a year. If the detection of asymptomatic metastases is considered to be advantageous then more frequent measurements of MCA may be required.
